Surat-based custom synthesis manufacturer of specialty chemicals, Anupam Rasayan India, has agreed to acquire 100% equity stake in Jayhawk Fine Chemicals Corporation, a US-based specialty chemical company, for a purchase consideration of around $150-mn (Rs. 1,348-crore).
The purchase consideration accounts for payment against the equity value of Jayhawk and existing loans payable to the existing shareholders. Considering ~$16-mn of cash and cash-like items for Jayhawk as of June-25, the purchase consideration translates to an enterprise value of ~$134-mn. The acquisition will be financed through a mix of internal accruals, debt and quasi equity from a leading global investment management firm.
Founded in 1941 and headquartered in Kansas, Jayhawk Fine Chemicals is part of the CABB Group and is engaged in custom manufacturing of advanced intermediates, active ingredients, and high-performance materials.
Anupam Rasayan said the acquisition will help expand its global CDMO presence and establish a strong foothold in the US & global specialty chemicals market.
This acquisition marks Anupam’s entry into onshore manufacturing in the US. Jayhawk’s US operations and customer base provides Anupam an immediate access to key end-markets and leading multinational customers, significantly enhancing its global reach and visibility.
The deal will boost Anupam’s polymer portfolio, adding high-value dianhydrides and polyimide intermediates to its offering. These products have critical applications across semiconductors and high-performance materials.
Over the past few years, Anupam has systematically strengthened the value chain - starting with acquisition of Tanfac, which secured raw material sourcing and ensured backward integration, particularly in fluorination chemistry.
“Now, with Jayhawk, we move forward in the value chain, closer to the end applications, manufacturing key N-1 molecules for these critical sectors,” said Mr. Anand Desai, Managing Director, Anupam Rasayan.
The combination of Jayhawk’s product portfolio and Anupam’s process expertise allows for forward integration across key molecules, enabling new downstream opportunities, he added.
Commenting on the rationale for the divestment, Mr. Tobias Schalow, CEO, CABB Group, said, “We have developed a scalable growth platform in Pharma and Life Science specialties, which we will further develop and expand, and shift away from industrial applications, electronics and semiconductors with this transaction.”


12 December, 2025 16:39:10 IST 

















